Table Info

Table 1.

Study design of protocol

Items	Parameters
Type of study	Case-control
Location	Centro Hospitalar Universitário de São João
Patients	Both genders and ≥ 60 years old
Cohorts	Cases: symptomatic CTS and surgical treatment indication
Cohorts	Controls: absence of symptomatic CTS and indication for hand surgical treatment
Exclusion criteria	Patients with diabetes mellitus, hypothyroidism, chronic renal failure under haemodialysis, rheumatoid arthritis and other inflammatory arthropathies, multiple myeloma, gout, chondrocalcinosis, Colles’s fracture, space-occupying lesions, or infectious synovitis

CTS: carpal tunnel syndrome

Declarations

Author contributions

SP and AM: Conceptualization, Investigation, Writing—original draft, Writing—review & editing. MC, BSP and ASP: Conceptualization. JS and IF: Writing—review & editing. PM, PN, JP and LC: Conceptualization. EM: Validation, Writing—original draft, Writing—review & editing, Supervision. All authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

The study protocol was approved by the Ethics Committee for Health of Centro Hospitalar Universitário de São João, reference No: CE 200/2020, and complied with the principles of the Helsinki Declaration.

Consent to participate

Informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.

Funding

This study is supported by a research grant from Pfizer Grant [59852013]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

Carlson RV, Boyd KM, Webb DJ. The revision of the Declaration of Helsinki: past, present and future. Br J Clin Pharmacol. 2004;57:695–713. [DOI] [PubMed] [PMC]

Cappelli F, Gallini C, Di Mario C, Costanzo EN, Vaggelli L, Tutino F, et al. Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. J Nucl Cardiol. 2019;26:497–504. [DOI] [PubMed]

Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, et al. Diagnosis, Prognosis, and Therapy of Transthyretin Amyloidosis. J Am Coll Cardiol. 2015;66:2451–66. [DOI] [PubMed]

Inês M, Coelho T, Conceição I, Duarte-Ramos F, de Carvalho M, Costa J. Epidemiology of Transthyretin Familial Amyloid Polyneuropathy in Portugal: A Nationwide Study. Neuroepidemiology. 2018;51:177–82. [DOI] [PubMed]

Sekijima Y, Uchiyama S, Tojo K, Sano K, Shimizu Y, Imaeda T, et al. High prevalence of wild-type transthyretin deposition in patients with idiopathic carpal tunnel syndrome: a common cause of carpal tunnel syndrome in the elderly. Hum Pathol. 2011;42:1785–91. [DOI] [PubMed]

Ruberg FL, Berk JL. Transthyretin (TTR) cardiac amyloidosis. Circulation. 2012;126:1286–300. [DOI] [PubMed] [PMC]

Nakagawa M, Sekijima Y, Yazaki M, Tojo K, Yoshinaga T, Doden T, et al. Carpal tunnel syndrome: a common initial symptom of systemic wild-type ATTR (ATTRwt) amyloidosis. Amyloid. 2016;23:58–63. [DOI] [PubMed]

Sperry BW, Reyes BA, Ikram A, Donnelly JP, Phelan D, Jaber WA, et al. Tenosynovial and Cardiac Amyloidosis in Patients Undergoing Carpal Tunnel Release. J Am Coll Cardiol. 2018;72:2040–50. [DOI] [PubMed]

Boyd K. The Council of Europe’s first Symposium on Bioethics: Strasbourg, Dec 5-7 1989. J Med Ethics. 1990;16:97–8. [DOI] [PubMed] [PMC]

10.

Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization. J Nucl Cardiol. 2020;27:659–73. [DOI] [PubMed]

11.

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018;379:1007–16. [DOI] [PubMed]

12.

Itzhaki Ben Zadok O, Abelow A, Vaxman I, Eisen A, Iakobishvili Z, Sagie A, et al. Prior Carpal Tunnel Syndrome and Early Concomitant Echocardiographic Findings Among Patients With Cardiac Amyloidosis. J Card Fail. 2020;26:909–16. [DOI] [PubMed]

13.

Ghali J, Murugasu A, Day T, Nicholls K. Carpal tunnel syndrome in fabry disease. JIMD Rep. 2012;2:17–23. [DOI] [PubMed] [PMC]

14.

Fenves AZ, Emmett M, White MG, Greenway G, Michaels DB. Carpal tunnel syndrome with cystic bone lesions secondary to amyloidosis in chronic hemodialysis patients. Am J Kidney Dis. 1986;7:130–4. [DOI] [PubMed]

15.

Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, et al.; THAOS Investigators. Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). J Am Coll Cardiol. 2016;68:161–72. [DOI] [PubMed] [PMC]